Clinical Trial

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

Study acronym: OPTIMIZE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-30
notable Trial sites reduced: 42 -> 15 locations 2026-07-30
Trial Details
NCT Number NCT07187115
Lead Sponsor Boston Scientific Corporation
Conditions Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Enrollment 699 participants
Start Date 2025-11-07
Primary Completion 2028-07 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29